Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Condylomata Acuminata 2Warts 1Prostatic Neoplasms 1Keratosis, Actinic 1High-grade Anal Intraepithelial Neoplasia 1Carcinoma, Basal Cell 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15Vaccines, Synthetic 10Papillomavirus Vaccines 7Vaccines 5Imiquimod 4Trichloroacetic Acid 3Gels 3human papillomavirus vaccine, L1 type 16, 18 2green tea extract polyphenone E 2Podophyllin 2Human Papillomavirus Recombinant Vaccine nonavalent 2Ethanol 2Duration of Therapy 2Cryotherapy 2Cantharidin 2ranpirnase 1polyphenon E 1nanocurcumin 1hecolin 1berdazimer sodium 1Zinc 1Viusid 1Vaccination 1VP-102 1Tuberculin 1Therapies, Investigational 1Tea 1Surgical Procedures, Operative 1PRA1 protein, Candida albicans 1Omiganan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Condylomata Acuminata × green tea extract polyphenone E × Clear all
NCT01490008 2012-04-19

Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers

MediGene

Phase 1 Completed
30 enrolled

Condylomata Acuminata

NCT01082302 2010-09-08

Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage

MediGene

Phase 4 Completed
43 enrolled

Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡